Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. - Test2 - elhamkhani - TriplyDB

Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.

Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.

http://www.wikidata.org/entity/Q33648864

about

Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab.Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

P2860

Q55360254-2444D0FC-6338-49AE-B48D-A7402C8A19F4 Q58121598-980A0018-96EB-488D-9451-8E4CBABC5974

P2860

Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.

http://www.wikidata.org/entity/Q33648864

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Epidemiological features of lu ...... d end results (SEER) database.

@ast

Epidemiological features of lu ...... d end results (SEER) database.

@en

type

label

Epidemiological features of lu ...... d end results (SEER) database.

@ast

Epidemiological features of lu ...... d end results (SEER) database.

@en

prefLabel

Epidemiological features of lu ...... d end results (SEER) database.

@ast

Epidemiological features of lu ...... d end results (SEER) database.

@en

P1433

Q33648864-3EE5C66F-57B8-449F-8335-5A0E8C176D8B

P1476

Q33648864-C43C4E69-C551-45CD-AEDD-F3B1114839F9

P2093

Q33648864-63DFAEAB-B6D9-4B54-A8EE-1795F8DF1680

Q33648864-A954E8B5-650F-4DEA-B9B3-ED25908E84AA

Q33648864-BBD4351E-2E90-4A4F-A3CD-B3D446D2672F

Q33648864-C26DD168-CAC3-4B62-A8C3-3B6BE20D15EE

Q33648864-C2ADFAD5-682E-46C2-9DAF-B4012923DCE8

Q33648864-C8D5628D-7889-4627-8B36-3E2762AA1784

Q33648864-DC34A68D-F27C-4A4D-8347-948A68061861

Q33648864-EB9BBEBF-C7F5-4491-B323-157DA389BBF8

Q33648864-F4BA43FA-30A9-4B0F-9BBB-221882D276AB

P2860

Q33648864-10250BC9-94F1-4069-AD95-3EBB1142DB7C

Q33648864-120D3787-0BB7-41A1-B124-9E2757234EE4

Q33648864-1B420D5B-A1C3-4F40-9F88-A3325CBB721F

Q33648864-1DEF068F-3A02-4AEF-8D37-C58186331161

Q33648864-1F8202DE-E594-47ED-A4CB-C9A5FCA6C61B

Q33648864-2A5D69ED-AEB4-4DCD-87C2-EB85771D411C

Q33648864-3201BE90-F763-4C5F-B0B5-9EEF4304B09A

Q33648864-38DBA012-334F-43D1-A4F6-D095EAB2AA46

Q33648864-391E710E-9DF8-4543-8327-4764ED912222

Q33648864-3D05B6DB-DDD8-4C43-A21B-490225316929

P304

Q33648864-EDE4FC27-8225-4373-90D5-6C2792FBF6BF

P31

Q33648864-CBE2AAEF-EF81-4E4F-AE53-1F30B75CCD6F

P356

Q33648864-B52AF4F7-6681-434A-B82E-4A37CAAB70E7

P407

Q33648864-B887AFDB-1D3A-4D2E-9129-5F555CE973D5

P433

Q33648864-EC3C65BA-4214-4575-89FB-501778979C30

P478

Q33648864-B2AE1ED1-8FFA-41B0-857F-BA872E26DE90

P577

Q33648864-82BB33E6-B30E-4520-B573-EBB9B720F98A

P698

Q33648864-1E8D4307-C1B7-4C96-ADA5-4692F1A28983

P932

Q33648864-6DA3D737-25CC-47A5-9F24-088BC8ACEB4E

P356

ONCOTARGET.15831

P1433

P1476

Epidemiological features of lu ...... d end results (SEER) database.

@en

P2093

Cai-Xia Dong

http://www.w3.org/2001/XMLSchema#string

Hong Shen

http://www.w3.org/2001/XMLSchema#string

Jia-Qi Chen

http://www.w3.org/2001/XMLSchema#string

Li-Zhen Zhu

http://www.w3.org/2001/XMLSchema#string

Shan-Shan Weng

http://www.w3.org/2001/XMLSchema#string

Xiu-Jun Tang

http://www.w3.org/2001/XMLSchema#string

Yi-Nuo Tan

http://www.w3.org/2001/XMLSchema#string

Ying Cao

http://www.w3.org/2001/XMLSchema#string

Ying Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Cancer statistics, 2015

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

The 2004 World Health Organization classification of lung tumors

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

P304

25323-25333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.15831

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28445978

http://www.w3.org/2001/XMLSchema#string

P932

5421933

http://www.w3.org/2001/XMLSchema#string